Risk of myocardial infarction associated with chronic hepatitis C virus infection: A population-based cohort study

Journal of Viral Hepatitis

Volumn 19, Issue 4, 2012, Pages 271-277

  Forde, K A ^a,b   Haynes, K ^b   Troxel, A B ^b   Trooskin, S ^a   Osterman, M T ^a,b   Kimmel, S E ^a,b   Lewis, J D ^a,b   Re III, V Lo ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

hepatitis C virus; inflammation; myocardial infarction

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEART INFARCTION; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84858297379     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01545.x     Document Type: Article

References (51)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10): 705-714. (Pubitemid 46780630)
2. Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45 (4): 219-226. (Pubitemid 36104853)
3. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52. (Pubitemid 32634271)
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341 (8): 556-562. (Pubitemid 29384163)
5. National institutes of health consensus development conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology (Baltimore, MD) 2002; 36 (5 Suppl. 1): S3-S20.
6. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334 (26): 1691-1696. (Pubitemid 26193620)
7. Kenny-Walsh E,. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340 (16): 1228-1233. (Pubitemid 29181642)
8. Seeff LB,. Natural history of chronic hepatitis C. Hepatology (Baltimore, MD) 2002; 36 (5 Suppl 1): S35-S46. (Pubitemid 35253462)
9. Zignego AL, Craxi A,. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12 (3): 611-636. ix. (Pubitemid 351958487)
10. Gershon AS, Margulies M, Gorczynski RM, Heathcote EJ,. Serum cytokine values and fatigue in chronic hepatitis C infection. J Viral Hepat 2000; 7 (6): 397-402.
11. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352 (16): 1685-1695.
12. Hansson GK, Libby P,. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6 (7): 508-519. (Pubitemid 43980523)
13. Libby P,. Inflammation in atherosclerosis. Nature 2002; 420 (6917): 868-874. (Pubitemid 36019640)
14. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133 (8): 592-599.
15. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology (Baltimore, MD) 2003; 38 (1): 50-56. (Pubitemid 36775795)
16. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC,. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology (Baltimore, MD) 2004; 40 (1): 115-119. (Pubitemid 38868929)
17. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ,. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 2007; 75 (3): 320-326. (Pubitemid 46074212)
18. Koike K,. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol Res 2005; 33 (2): 145-150. (Pubitemid 41799793)
19. Momiyama Y, Ohmori R, Kato R, Taniguchi H, Nakamura H, Ohsuzu F,. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 2005; 181 (1): 211-213. (Pubitemid 40804713)
20. Vassalle C, Masini S, Bianchi F, Zucchelli GC,. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90 (5): 565-566. (Pubitemid 38530180)
21. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA,. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; 43 (6): e53-e56.
22. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359 (9301): 133-135. (Pubitemid 34112545)
23. Ishizaka Y, Ishizaka N, Takahashi E, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67 (1): 26-30. (Pubitemid 36119617)
24. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103 (8): 1064-1070. (Pubitemid 32200178)
25. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, Petrobelli F,. Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up. Angiology 2008; 59 (6): 717-720.
26. Bilora F, Rinaldi R, Boccioletti V, Petrobelli F, Girolami A,. Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. Gastroenterol Clin Biol 2002; 26 (11): 1001-1004. (Pubitemid 35440173)
27. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T,. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA 2003; 289 (10): 1245-1246. (Pubitemid 37432904)
28. Volzke H, Schwahn C, Wolff B, et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004; 174 (1): 99-103. (Pubitemid 38595446)
29. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC,. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49 (2): 225-232.
30. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL,. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16 (4): 393-401. (Pubitemid 46656860)
31. Lis Y, Mann RD,. The VAMP Research multi-purpose database in the U.K. J Clin Epidemiol 1995; 48 (3): 431-443.
32. Chisholm J,. The Read clinical classification. Br Med J 1990; 300 (6732): 1092. (Pubitemid 20158094)
33. Garcia Rodriguez LA, Perez Gutthann S,. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45 (5): 419-425. (Pubitemid 28227341)
34. Lo Re V III, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD,. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009; 18 (9): 807-814.
35. Haynes K, Bilker WB, Tenhave TR, Strom BL, Lewis JD,. Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf 2011; 20 (9): 948-955.
36. Hammad TA, McAdams MA, Feight A, Iyasu S, Dal Pan GJ,. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008; 17 (12): 1197-1201.
37. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311 (13): 819-823. (Pubitemid 14035089)
38. Cox D,. Regression models and life tables. J R Stat Soc Ser 1972; 34: 187-220.
39. Rothman KJ, Greenland S,. Modern Epidemiology, 2nd edn. Philadelphia: Lippincott Williams and Wilkins, 1998.
40. Rubin DB,. Multiple Imputation for Nonresponse in Surveys. New York: Wiley, 1987.
41. Little RJA, Rubin DB,. Statistical Analysis with Missing Data. New York: Wiley, 1989.
42. StataCorp. Stata: Release 11. Multiple-Imputation Reference Manual. College Station, TX: Stata Press, 2009.
43. Li KH,. Imputation using Markov chains. J Stat Comput Simulation 1988; 30: 57-79.
44. Lewis JD, Bilker WB, Weinstein RB, Strom BL,. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14 (7): 443-451. (Pubitemid 40990739)
45. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107 (9): 1303-1307. (Pubitemid 36314415)
46. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296 (14): 1735-1741. (Pubitemid 44547793)
47. Nikpour M, Urowitz MB, Gladman DD,. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31 (2): 329-354. Vii-viii. (Pubitemid 40732492)
48. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A,. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44 (12): 2737-2745. (Pubitemid 34016192)
49. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44 (10): 2331-2337. (Pubitemid 32977500)
50. Ward MM,. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42 (2): 338-346. (Pubitemid 29072852)
51. Marzouk D, Sass J, Bakr I, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56 (8): 1105-1110. (Pubitemid 47123241)